Sjögren's Disease

R. Hal Scofield, MD, discusses exploratory biomarker analyses from DAHLIAS investigating serotype, IFN, and IgG subgroups.

April is Sjögren's Awareness Month and we took a look at how the field's fast-growing pipeline is reshaping care.

Wells and Troum discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases.

Grader-Beck emphasized the potential of ianalumab for improving treatment options for Sjögren disease.

Novartis plans to submit regulatory applications for ianalumab in early 2026.

Ianalumab significantly reduces Sjögren disease activity, meeting the primary outcome in recent phase 3 trials.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

Novartis is planning regulatory submissions for the therapy, which could become the first to meaningfully modify disease activity.

Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.

Jacques-Eric Gottenberg, MD, PhD, discusses the encouraging results of a phase 2 study evaluating nipocalimab for the treatment of Sjögren's syndrome.

Promising results of the phase 2 and 3 trials offer hope for patients with chronic and debilitating autoantibody-driven diseases.